Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/10/2025 | $38.00 | Mkt Outperform | Citizens JMP |
| 10/8/2024 | $44.00 | Buy | Guggenheim |
| 10/8/2024 | $40.00 | Buy | Stifel |
| 10/8/2024 | $35.00 | Buy | Jefferies |
| 10/8/2024 | $30.00 | Overweight | JP Morgan |
4 - MBX Biosciences, Inc. (0001776111) (Issuer)
4 - MBX Biosciences, Inc. (0001776111) (Issuer)
4 - MBX Biosciences, Inc. (0001776111) (Issuer)
CARMEL, Ind., April 22, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at and participate in the Citizens Life Sciences Conference on May 7 and the RBC 2025 Global Healthcare Conference on May 21. The Citizens Life Sciences Conference Date: Wednesday, May 7, 2025Format: Fireside chat and 1x1 meetingsTime: 3:00 p.m. – 3:25 p.m. ETLocation: New York, NY The RBC 2025 Global Healthcare Conference Date: Wednesday, Ma
CARMEL, Ind., April 07, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Steve Hoerter as an independent director to the Company's Board of Directors. Mr. Hoerter brings over three decades of pharmaceutical commercialization and executive leadership experience as well as a proven track record of building and growing life science companies. "I am thrilled to welcome Steve Hoerter to the Company's Board as an independent director," said Kent Hawryluk, President and Chief
CARMEL, Ind., March 26, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at and participate in the 24th Annual Needham Virtual Healthcare Conference. 24th Annual Needham Virtual Healthcare Conference Date: Monday, April 7, 2025Format: Podium Presentation and 1x1 meetingsTime: 8:00 a.m. – 8:40 a.m. ET The live webcast can be accessed in the investors section of the MBX Biosciences website at https://investors.mbxbio.
4 - MBX Biosciences, Inc. (0001776111) (Issuer)
4 - MBX Biosciences, Inc. (0001776111) (Issuer)
3 - MBX Biosciences, Inc. (0001776111) (Issuer)
CARMEL, Ind., April 07, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Steve Hoerter as an independent director to the Company's Board of Directors. Mr. Hoerter brings over three decades of pharmaceutical commercialization and executive leadership experience as well as a proven track record of building and growing life science companies. "I am thrilled to welcome Steve Hoerter to the Company's Board as an independent director," said Kent Hawryluk, President and Chief
Chatan Charan, Ph.D. appointed as Senior Vice President, Pharmaceutical Development and CMC Mark Hope appointed as Senior Vice President, Regulatory and Quality CARMEL, Ind., March 05, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointments of Chatan Charan, Ph.D. as Senior Vice President, Pharmaceutical Development and Chemistry, Manufacturing and Controls (CMC) and Mark Hope as Senior Vice President, Regulatory and Quality. "We are excited to welcome Chatan and Mark, who wi
Phase 1 results support proceeding to Phase 2 in patients with post-bariatric hypoglycemia (PBH), which is expected to begin in 2H 2025 Phase 1 trial in healthy volunteers showed MBX 1416 was generally well-tolerated with a favorable safety profile Pharmacokinetic results demonstrated sustained dose-dependent exposure and support once-weekly dosing Company to host conference call to discuss results today at 8:30 am ET CARMEL, Ind., Jan. 07, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today annou
SC 13G - MBX Biosciences, Inc. (0001776111) (Subject)
SC 13G - MBX Biosciences, Inc. (0001776111) (Subject)
SC 13D - MBX Biosciences, Inc. (0001776111) (Subject)
DEFA14A - MBX Biosciences, Inc. (0001776111) (Filer)
DEF 14A - MBX Biosciences, Inc. (0001776111) (Filer)
8-K - MBX Biosciences, Inc. (0001776111) (Filer)
Citizens JMP initiated coverage of MBX Biosciences with a rating of Mkt Outperform and set a new price target of $38.00
Guggenheim initiated coverage of MBX Biosciences with a rating of Buy and set a new price target of $44.00
Stifel initiated coverage of MBX Biosciences with a rating of Buy and set a new price target of $40.00